Anas Bizanti
Overview
Explore the profile of Anas Bizanti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wills W, Reyes P, Amon A, Lugo L, Bizanti A, Bugajski A
J Cardiovasc Nurs
. 2025 Mar;
PMID: 40030055
Background: Cardiovascular diseases (CVDs) and chronic obstructive pulmonary disease (COPD) often occur comorbidly, sharing similar risk factors and symptom presentations. However, the influence of comorbid CVD on health-related quality of...
2.
Sabina M, Shah S, Grimm M, Daher J, Campillo P, Boozo M, et al.
J Clin Med
. 2025 Jan;
14(1.
PMID: 39797234
The benefit of beta-blockers (BBs) for myocardial infarction (MI) patients with a preserved left ventricular ejection fraction (LVEF) is uncertain. While beneficial for a reduced LVEF, their efficacy with a...
3.
Rivera-Martinez J, Sabina M, Khanani A, Lurie A, Rigdon A, Abusnina W, et al.
Cardiovasc Drugs Ther
. 2025 Jan;
PMID: 39754661
Purpose: Heart failure (HF) management is well-defined for reduced ejection fraction (HFrEF) but less so for mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF). This meta-analysis evaluates the impact of...
4.
Sabina M, Trube J, Shah S, Lurie A, Grimm M, Bizanti A
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518537
Finerenone, a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), offers a targeted approach to managing cardiovascular outcomes, particularly in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Unlike...
5.
Campillo P, Kesler A, Ramirez C, Ramirez C, Daher J, Grimm M, et al.
Melanoma Res
. 2024 Oct;
35(1):24-30.
PMID: 39365850
The incidence of heart transplants in the USA has increased by 85.8% since 2011, resulting in a growing population of recipients requiring long-term immunosuppressive therapy. While essential for preventing organ...
6.
Al-Abdouh A, Samadi D, Sukhon F, Mhanna M, Jabri A, Alhuneafat L, et al.
Am J Cardiol
. 2024 Sep;
231:82-89.
PMID: 39222739
In-stent restenosis (ISR) accounts for 10% of percutaneous coronary intervention (PCI) in the United States. Paclitaxel-coated balloons (PCBs) have been evaluated as a therapy for coronary ISR in multiple randomized...
7.
Al-Abdouh A, Abusnina W, Mhanna M, Barbarawi M, Jabri A, Bizanti A, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
1(5):100397.
PMID: 39131480
Background: Vascular access closure is essential in large-bore arteriotomy procedures, such as transcatheter aortic valve replacement. Suture-based devices are frequently used for vascular access closure. MANTA (Teleflex) is a collagen...
8.
Abusnina W, Al-Abdouh A, Bizanti A, Gill G, Houssien A, Alshebani Y, et al.
Cardiovasc Revasc Med
. 2021 Aug;
38:54-60.
PMID: 34384690
Background: The role of P2Y12 inhibition in acute coronary syndrome (ACS) has been well described in literature. However, the agent of choice is less clear among elderly patients (>65 years)...
9.
Bizanti A, Bizanti A, Al-Abdouh A, Mohammed M, Pardi M
Case Rep Oncol Med
. 2021 May;
2021:5575957.
PMID: 33936825
Neurofibromatosis type 1 (NF-1) is known to be associated with increased risk of malignancy by at least fourfold. Malignant lymphomas are rare in adults with NF-1. Hereby, we present a...
10.
Al-Abdouh A, Bizanti A, Barbarawi M, Jabri A, Kumar A, Fashanu O, et al.
Contemp Clin Trials
. 2021 Jan;
101:106272.
PMID: 33422642
Background: The nucleotide analogue prodrug remdesivir was among the first antiviral therapies to be tested in randomized controlled trials (RCTs) for COVID-19. We performed a meta-analysis to understand efficacy and...